Overview

Update
IPO / Stock
Went Public on Jun 28, 2012 / NASDAQ:TSRO
Total Equity Funding
$161M in 2 Rounds from 7 Investors
Headquarters:
Waltham, MA
Description:
TESARO is an oncology-focused biopharmaceutical company identifying better cancer therapies to improve the lives of patients with cancer.
Founders:
,
Categories:
Biopharma, Health Care, Biotechnology
Website:
http://tesarobio.com
Social:

Company Details

Update

Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients. TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications. Phase 3 clinical testing of rolapitant is planned to commence during 2011 and the first ALK inhibitor clinical trial is targeted to begin in 2012. TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion. TESARO is headquartered in Waltham, Massachusetts.

Funding Rounds (5) - $457M

Update
DateAmount / RoundValuationLead InvestorInvestors
Apr, 2016$50M / Post Ipo Equity1
Mar, 2016$155M / Post Ipo Equity5
Mar, 2013$91M / Post Ipo Equity0
Jun, 2011$101M / Series B7
May, 2010$60M / Series A1

Current Team (6)

Update

Offices/Locations (1)

Update
  • Headquarters

    1000 Winter St

    Suite #3300

    Waltham, MA 02451

    USA

Past Team (1)

Update

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos